These industry-organised sessions are open only to registered NordCoag delegates and are primarily intended for healthcare professionals and researchers.
Limited space: Max 25 participants.
Register early to secure your spot. Booked seats are held until 10 minutes before the session starts.
12:30 – 13:15
Novo Nordisk / Novel Treatment Strategies and Perioperative Management in Haemophilia B
12:30-12:35 Welcome and introduction / Göran Klement*
12:35-12:45 Unmet needs in Haemophilia B and rationale for novel therapies / Víctor Jiménez-Yuste**
12:45-13:05 Anti‑TFPI treatments in Haemophilia B: opportunities and challenges / Víctor Jiménez-Yuste**
13:05-13:15 Case presentations / Víctor Jiménez-Yuste**
13:15 Thank you and close / Göran Klement*
*National Medical Advisor Rare Disease, Novo Nordisk
**Professor of Medicine, Universidad Autónoma de Madrid / Head of the Department of Haematology, Hospital Universitario La Paz, Madrid, Spain
Takeda / Von Willebrand Disease throughout life
12:30-12:35 Welcome and introduction / Jan Astermark*
12:35-12:45 Von Willebrand Disease in Children: Early recognition and Practical Management / Tony Frisk
12:45-13:05 Adult von Willebrand Disease: Practical Management and Long-Term care / Riitta Lassila**
13:05-13:15 Moderated discussion and Q&A / Jan Astermark
* Professor of Clinical Coagulation, Head of the Department of Translational Medicine, Lund University / Head of the Coagulation Unit, Skåne University Hospital, Malmö, Sweden
**Professor of Coagulation Medicine, University of Helsinki, Finland
08:00 – 08:45
Pfizer/ From Trial to Treatment Centre: Marstacimab OLE Updates and Practical Insights from the Clinic
08.00-08.05 Welcome and introduction / Maria Bruzelius
08.05-08.20 Presentation BASIS OLE study marstacimab / Ana Boban*
08.20-08.35 Patient cases and treatment experience with Hympavzi (marstacimab)/ Florian Langer**
08.35-08.45 Discussion and closing remarks / Maria Bruzelius
* Professor of Internal Medicine, University of Zagreb School of Medicine / Head of the Haemophilia Centre, University Hospital Centre Zagreb, Croatia
** Professor, Head of the Haemostasis Unit, Department of Internal Medicine II / University Medical Center Hamburg-Eppendorf, Germany
12:20 – 13:05
Roche / When the Future Becomes the Norm – The Recent Evolution of the Therapeutic Landscape for Hemophilia A
12:20-12:25 Welcome and Introduction / Anna-Elina Armstrong*
12:25-12:45 The Recent Evolution of the Therapeutic Landscape for Hemophilia A in the UK / Gerry Dolan**
12:45-12:55 What About the Older Adults – Should we Evolve our Care Paradigms as Well? / Gerry Dolan**
12:55-13:05 The Nordic Perspective – An Interactive Discussion on Translating Paradigms into Practice / Anna-Elina Armstrong*
* Senior Consultant, Coagulation Disorders Centre, Division of Haematology / Helsinki University Hospital, Finland
** Consultant Haematologist, Director of the Haemophilia Comprehensive Care Centre / St Thomas’ Hospital, London, United Kingdom
Sobi / From Bleed Prevention to Life Long Joint Health – Will Normalized Haemostasis in Haemophilia A take us there?
This practical HEAD-US session will be delivered twice to accommodate all participants. Attendees
will participate in one of the two identical sessions
Session 1:
12:20-12:40
Session 2:
12:45-13:05
- Introduction: Synovitis as a key driver of joint disease / Jan Astermark*
- Live Demonstration: From Imaging to Decisions – HEAD US in Practice / Magnus Aspdahl** & Jan Astermark*
- Discussion and Closing remarks / Jan Astermark*
** Professor of Clinical Coagulation, Head of the Department of Translational Medicine, Lund University / Head of the Coagulation Unit, Skåne University Hospital, Malmö, Sweden
**Senior Physiotherapist, Karolinska University Hospital, Sweden
08:00 – 08:45
Bayer / DO NOT TAKE IT PERSONALLY. Be personalized
08:00-08:05 Welcome and introduction / Erik Berntorp¹
08:05-08:15 Now we have the tools – just go ahead! / Sonata Šaulytė Trakymienė²
08:15-08:25 Personalized FVIII treatment is the future! / Pål André Holme³
08:25-08:35 Rebuttal and audience voting / Erik Berntorp¹
08:35-08:45 Summary and conclusion / Erik Berntorp¹
¹ Professor Emeritus of Clinical Coagulation / Lund University, Malmö, Sweden
² Paediatric Haematologist, Head of the Coordinating Centre for Haemophilia and Coagulation Disorders, Vilnius University Hospital Santaros Klinikos, Lithuania
³ Professor of Haematology, Head of the Department of Haematology, Oslo University Hospital / University of Oslo, Norway
